DOAC Preference for Cerebral Venous Sinus Thrombosis
For cerebral venous sinus thrombosis (CVST), apixaban or rivaroxaban are the preferred DOACs, with apixaban showing the strongest safety profile in recent evidence. Start with apixaban 10 mg twice daily for 7 days, then 5 mg twice daily for maintenance therapy.
Dosing Regimens
Apixaban (Preferred)
- Initial phase: 10 mg orally twice daily for 7 days
- Maintenance: 5 mg orally twice daily
- No parenteral lead-in required 1
Rivaroxaban (Alternative)
- Initial phase: 15 mg orally twice daily with food for 21 days
- Maintenance: 20 mg once daily with food
- No parenteral lead-in required 1
Dabigatran or Edoxaban (Less Preferred)
- Require 5-10 days of parenteral anticoagulation (LMWH) before initiation
- This delays oral therapy and complicates treatment 1
Evidence Supporting DOAC Use in CVST
While traditional guidelines have recommended vitamin K antagonists (VKAs) for CVST, emerging high-quality evidence demonstrates DOACs are non-inferior and potentially safer:
The 2025 DOAC-CVT prospective international cohort study (619 patients) found no difference in the composite endpoint of symptomatic VTE and major bleeding at 6 months between DOACs and VKAs (3% vs 3%, weighted OR 0.99) 2
A 2025 meta-analysis of 4,929 patients showed DOACs significantly reduced recurrent VTE (RR 0.84, p=0.04) and intracranial hemorrhage (RR 0.67, p=0.007) compared to VKAs, with comparable rates of major bleeding and mortality 3
Network meta-analysis data indicates apixaban has the highest probability of reducing VTE recurrence (P-score 0.83), ICH (P-score 0.70), major hemorrhage (P-score 0.81), and mortality (P-score 0.78) among all anticoagulants 4
Practical Considerations
Timing of DOAC initiation: Most patients in real-world practice receive initial parenteral anticoagulation (typically LMWH) before transitioning to DOACs, with median delay of 24 days from diagnosis 5. However, apixaban and rivaroxaban can be started immediately without parenteral lead-in, which is advantageous.
Treatment duration: Minimum 3 months for all VTE including CVST 6, 7. For unprovoked CVST, consider extended-phase anticoagulation with reassessment at 6 months. After 6 months, reduced-dose options become available:
Critical Caveats
Renal function: DOACs require dose adjustment or avoidance in severe renal dysfunction (CrCl <30 mL/min for most DOACs). In such cases, transition to VKA may be necessary 1
Drug interactions: Screen for significant drug-drug interactions, particularly with strong CYP3A4 and P-glycoprotein inhibitors/inducers 1
Pregnancy/lactation: Absolute contraindication to DOACs; use LMWH instead 2
Active cancer: While DOACs are preferred over VKAs for cancer-associated VTE generally 1, CVST in cancer patients requires individualized assessment given higher bleeding risks with certain malignancies (GI, genitourinary) 1
Why Apixaban Over Other DOACs
The preference for apixaban stems from:
- No parenteral lead-in required - immediate oral therapy possible
- Twice-daily dosing may provide more stable anticoagulation
- Strongest safety signals in network meta-analyses for hemorrhagic complications 4
- Most prescribed DOAC in real-world CVST registries (53.3% of cases) 5
Rivaroxaban remains an excellent alternative, particularly if once-daily dosing improves adherence. The key advantage of both over dabigatran/edoxaban is avoiding the mandatory parenteral lead-in period, which simplifies acute management and potentially reduces hospital length of stay 9.